ONCOLOGY-NEW YORK

Scope & Guideline

Advancing Cancer Research, One Article at a Time.

Introduction

Welcome to the ONCOLOGY-NEW YORK information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of ONCOLOGY-NEW YORK, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0890-9091
PublisherUBM MEDICA
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1987 to 2024
AbbreviationONCOLOGY-NY / Oncology-NY
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854

Aims and Scopes

The journal 'ONCOLOGY-NEW YORK' focuses on advancing knowledge and practice in the field of oncology by publishing peer-reviewed articles that cover a broad spectrum of cancer-related topics. Its aims and scopes reflect both clinical and research aspects of oncology, emphasizing innovative treatments, patient care strategies, and the integration of new technologies in cancer management.
  1. Clinical Trials and New Treatments:
    The journal extensively covers findings from clinical trials, particularly those that introduce novel therapies or treatment combinations for various cancers, including hematological malignancies and solid tumors.
  2. Multidisciplinary Approaches:
    A strong emphasis is placed on the importance of a multidisciplinary approach in oncology, integrating insights from surgery, medical oncology, radiation therapy, and supportive care to enhance patient outcomes.
  3. Emerging Technologies and Innovations:
    The journal highlights advancements in technology, such as artificial intelligence and liquid biopsy, that have the potential to transform cancer diagnosis and treatment.
  4. Patient-Centric Care and Quality of Life:
    Research focusing on patient experiences, psychosocial aspects of cancer treatment, and strategies for improving quality of life for cancer patients is a consistent theme.
  5. Health Equity and Access to Care:
    The journal addresses disparities in cancer care, advocating for equitable access to treatment and highlighting the impact of socioeconomic factors on cancer outcomes.
Recent publications in 'ONCOLOGY-NEW YORK' indicate emerging trends that reflect the evolving landscape of oncology research and practice. These trends highlight new areas of focus that are gaining traction among researchers and clinicians alike.
  1. Immunotherapy and Targeted Therapies:
    There is a significant increase in research surrounding immunotherapies and targeted treatments, particularly in hematologic malignancies and solid tumors, showcasing their transformative potential in cancer care.
  2. Artificial Intelligence in Oncology:
    The integration of artificial intelligence to improve treatment outcomes and patient management strategies is a rapidly growing theme, reflecting the broader trend of utilizing technology to enhance healthcare delivery.
  3. Patient-Reported Outcomes and Quality of Life:
    An increasing emphasis on patient-reported outcomes and the quality of life of cancer patients is evident, highlighting the importance of holistic care and patient-centered approaches in oncology.
  4. Genomic and Biomarker Research:
    The exploration of genomic profiling and biomarkers for predicting treatment responses and personalizing therapy is trending, indicating a move towards precision medicine in oncology.
  5. Health Equity and Disparities in Cancer Care:
    Discussions around health equity and addressing disparities in cancer treatment access are becoming more prominent, reflecting growing awareness and advocacy for equitable healthcare solutions.

Declining or Waning

While 'ONCOLOGY-NEW YORK' continues to evolve, certain themes have shown a decline in prominence in recent publications. This may reflect shifting priorities within the oncology community or changes in research funding and interest.
  1. Traditional Chemotherapy Protocols:
    As newer targeted therapies and immunotherapies gain traction, traditional chemotherapy protocols are being discussed less frequently, indicating a shift towards more personalized treatment approaches.
  2. Historical Perspectives on Cancer Treatment:
    There appears to be a waning interest in retrospective analyses of older treatment regimens, as the focus shifts towards innovative and cutting-edge therapies.
  3. General Oncological Guidelines Without Specificity:
    Broad discussions around general oncology guidelines are becoming less common, replaced by more specific studies and recommendations tailored to individual cancer types or patient populations.

Similar Journals

World Journal of Clinical Oncology

Exploring Innovations in Clinical Oncology
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Nature Reviews Clinical Oncology

Shaping the Future of Oncology with Evidence
Publisher: NATURE PORTFOLIOISSN: 1759-4774Frequency: 12 issues/year

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

Advances in Radiation Oncology

Empowering Oncology through Open Access Insights
Publisher: ELSEVIER INCISSN: Frequency: 4 issues/year

Advances in Radiation Oncology, published by Elsevier Inc, is a premier international journal dedicated to the field of oncology and radiology, focusing on the latest groundbreaking research and innovations in radiation therapy. Launched as an Open Access journal in 2016, it has since carved out a significant niche in the academic community, featuring contributions that span a diverse range of topics including clinical practices, technologies, and outcomes in radiation oncology. With an impressive Q2 rankingOncology and Radiology, Nuclear Medicine and Imaging categories for 2023, and positioned within the 65th and 55th percentiles of Scopus ranks, it serves as an essential resource for researchers, medical professionals, and students alike. The journal not only emphasizes the importance of disseminating knowledge widely through its open access model but also aims to foster collaboration and innovation in the evolving landscape of cancer treatment. For those looking to stay at the forefront of radiotherapy research and advancements, Advances in Radiation Oncology is an invaluable platform for scholarly communication.

ANNALS OF ONCOLOGY

Leading the charge in cancer care and clinical practice.
Publisher: ELSEVIERISSN: 0923-7534Frequency: 12 issues/year

ANNALS OF ONCOLOGY, published by Elsevier, stands as a premier journal in the field of oncology, hematology, and general medicine, with a notable impact factor that underscores its significance in advancing cancer research and clinical practice. Established in 1990, this journal has become a highly respected source of information, consistently ranked in the Q1 category in its respective fields, showcasing its influence and credibility (Rank #4/404 in Oncology and Rank #2/137 in Hematology as per Scopus rankings). With a focus on innovative therapies, clinical trials, and emerging research, ANNALS OF ONCOLOGY serves as an essential resource for researchers, clinicians, and students dedicated to unraveling the complexities of cancer treatment and care. Although offering restricted access options, its impactful studies and discoveries continue to shape the future of oncology.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Transforming Oncology with Innovative Research and Clinical Strategies.
Publisher: SPRINGERISSN: 0171-5216Frequency: 12 issues/year

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

JNCI Cancer Spectrum

Advancing cancer research for a brighter tomorrow.
Publisher: OXFORD UNIV PRESSISSN: Frequency: 6 issues/year

JNCI Cancer Spectrum, published by Oxford University Press, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. With an impressive impact demonstrated through its Q1 ranking in both Cancer Research and Oncology categories for 2023, this journal provides a vital platform for disseminating high-quality research and innovative findings in a rapidly evolving landscape. Since its inception in 2017, JNCI Cancer Spectrum has embraced open access, enhancing the accessibility of evidence-based knowledge to researchers, professionals, and students across the globe. Additionally, it boasts notable positions in Scopus rankings, with a strong performance in both the Medicine and Biochemistry, Genetics and Molecular Biology categories. The journal is committed to its objectives of fostering collaborative efforts and encouraging dialogue among experts, making it an essential resource for anyone involved in cancer research.

International Journal of Clinical Oncology

Connecting Researchers to Transform Patient Outcomes
Publisher: SPRINGER JAPAN KKISSN: 1341-9625Frequency: 6 issues/year

International Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.

LANCET ONCOLOGY

Discovering innovative solutions for complex oncology challenges.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

ONCOLOGIST

Uniting voices in the fight against cancer.
Publisher: OXFORD UNIV PRESSISSN: 1083-7159Frequency: 12 issues/year

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.

BREAST

Exploring breakthroughs in breast disease management.
Publisher: CHURCHILL LIVINGSTONEISSN: 0960-9776Frequency: 6 issues/year

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.